8-K: DaVita Reports Q1 2026 Financial Results

DaVita Inc. announced its first quarter 2026 financial and operating results, reporting consolidated revenues of $3.416 billion and diluted earnings per share of $2.87.

Summary

• DaVita Inc. reported its financial and operating results for the first quarter ended March 31, 2026.
• Consolidated revenues reached $3.416 billion.
• Operating income was $482 million, representing a 14.1% operating margin.
• Diluted earnings per share from continuing operations were $2.87.
• Operating cash flow was $321 million, and free cash flow was $140 million.
• The company repurchased 3.0 million shares of common stock for $403 million during the quarter.
• As of March 31, 2026, DaVita provided dialysis services to approximately 296,300 patients across 3,262 outpatient centers globally.
• Integrated kidney care arrangements covered approximately 62,600 patients, representing $5.4 billion in annualized medical spend.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with solid operational results and clear forward guidance, but offset by increasing costs and debt levels.

Positives

• Consolidated revenues increased to $3.416 billion.
• Operating income improved to $482 million, with a healthy operating margin of 14.1%.
• Diluted earnings per share from continuing operations were strong at $2.87.
• Positive operating cash flow of $321 million was generated.
• Free cash flow of $140 million indicates the company's ability to generate cash after capital expenditures.
• Significant share repurchases totaling $403 million demonstrate a commitment to returning capital to shareholders.
• Revenue per treatment increased to $417.59 compared to the prior year quarter ($400.14).

Negatives

• Patient care costs per treatment increased to $280.11 from $271.77 in the prior year quarter.
• General and administrative expenses increased to $320 million from $283 million in the prior year quarter.
• Free cash flow decreased to $140 million from $1,444 million in the prior year (though this is a twelve-month comparison, the quarterly free cash flow was $140M vs -$45M in Q1 2025).
• Total debt increased to $10.694 billion from $9.799 billion in the prior year quarter.

Risks

• Potential impacts from cybersecurity incidents experienced in 2025.
• Uncertainty surrounding the One Big Beautiful Bill Act (OBBBA) and federal government policy changes affecting reimbursement rates.
• Supply chain challenges and disruptions, including impacts from evolving trade policies and tariffs.
• Increased competition from other dialysis providers and new market entrants.
• The impact of new or innovative technologies, drugs, or treatments on the dialysis industry.
• Elevated teammate turnover or labor costs.
• Downward pressure on average realized payment rates from commercial payor plans.
• Risks associated with laws, regulations, and potential litigation impacting coverage or reimbursement rates.

Future Outlook

DaVita has provided 2026 guidance for Adjusted Operating Income between $2,150 million and $2,250 million, Adjusted Diluted Net Income per Share from Continuing Operations between $14.10 and $15.20, and Free Cash Flow between $1,000 million and $1,250 million. The company also provided normalized treatment days by quarter for 2025 and 2026.

Management Comments

• "DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results," said Javier Rodriguez, CEO of DaVita Inc.
• "We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception."

Industry Context

StockSavvy.ai notes that DaVita's Q1 2026 results reflect continued operational strength in the dialysis sector, a market characterized by stable demand but increasing competitive and regulatory pressures. The company's focus on clinical excellence and integrated care models aligns with broader healthcare trends towards value-based care.

Comparison to Industry Standards

• DaVita's operating margin of 14.1% for Q1 2026 is a key indicator of its profitability within the dialysis services industry. While direct comparisons to specific private companies are difficult, publicly traded peers in the healthcare services sector often exhibit margins that vary widely based on their specific business models and service offerings.
• The company's revenue per treatment of $417.59 is a critical metric. Industry benchmarks for revenue per treatment can fluctuate based on payor mix, geographic location, and service intensity. DaVita's reported figure should be assessed against its historical performance and any available industry data for similar service providers.
• DaVita's reported free cash flow of $140 million for the quarter, and $1.209 billion for the trailing twelve months, demonstrates its capacity to generate cash. This metric is crucial for assessing financial flexibility, debt repayment ability, and potential for shareholder returns, and is a common benchmark across many industries.

Legal Proceedings

• The filing mentions an accrual for potential third-party judgment costs for certain legal matters, which is excluded from non-GAAP metrics.

Related Party Transactions

• Due to related party balance of $86.5 million as of March 31, 2026, compared to $199.94 million as of December 31, 2025.

Stakeholder Impact

• Shareholders: The company repurchased $403 million in stock, potentially increasing shareholder value through reduced share count. The guidance provided offers visibility into future performance.
• Employees: The filing notes potential for elevated teammate turnover or labor costs, which could impact employee morale and operational efficiency.
• Creditors: The increase in total debt to $10.694 billion and a leverage ratio of 3.34x may be a point of consideration for creditors regarding the company's debt servicing capacity.
• Patients: Continued focus on clinical excellence and integrated care models aims to improve patient outcomes and management of chronic kidney disease.

Next Steps

• DaVita will hold a conference call on May 5, 2026, at 5:00 p.m. Eastern Time to discuss its first quarter results.
• The company will continue to execute its strategic initiatives, including Integrated Kidney Care (IKC) and Value-Based Care (VBC) programs.
• Ongoing share repurchases are expected to continue as part of the capital allocation plan.

Key Dates

Recommendation

The filing presents a stable operational quarter with clear guidance, but the increase in debt, rising patient care costs, and ongoing industry risks suggest a cautious approach. While the company is performing as expected, significant catalysts for a strong buy are not evident, and potential headwinds warrant a hold recommendation.

Keywords

DaVita Inc., 8-K, Financial Results, Q1 2026, Dialysis, Healthcare, Earnings Per Share, Revenue